Pallini, Greece

Morfis Abatzis

This inventor holds 1 USPTO granted patent and 5 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignee: Pharmathen S.a.. Active years: 2021.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Morfis Abatzis: Innovator in Pharmaceutical Compositions

Introduction

Morfis Abatzis is a notable inventor based in Pallini Attikis, Greece. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patent related to delayed release pharmaceutical compositions.

Latest Patents

Morfis Abatzis holds a patent for "Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof." This invention focuses on a delayed release pharmaceutical composition that includes a fumaric acid ester, such as Dimethyl fumarate, formulated in gastro-resistant tablets filled into hard gelatin capsules. This advancement has the potential to improve the efficacy and patient compliance of pharmaceutical treatments.

Career Highlights

Morfis Abatzis is associated with Pharmathen S.A., a company known for its commitment to developing high-quality pharmaceutical products. His work at Pharmathen has allowed him to contribute to the advancement of pharmaceutical sciences and improve therapeutic options available to patients.

Collaborations

Morfis has collaborated with notable colleagues, including Evangelos Karavas and Efthymios Koutris. Their combined expertise has fostered a productive environment for innovation and development within the pharmaceutical sector.

Conclusion

Morfis Abatzis stands out as an influential inventor in the pharmaceutical industry, with a focus on innovative compositions that enhance drug delivery. His contributions continue to shape the future of pharmaceutical formulations and patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…